Acadia Pharmaceuticals (ACAD) Shares Outstanding (Weighted Average) (2010 - 2026)

Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $170.5 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 2.22% year-over-year to $170.5 million; the TTM figure through Mar 2026 stood at $170.5 million (up 2.22% YoY), while the FY2025 annual figure was $168.4 million, up 1.59% from the prior year.
• Shares Outstanding (Weighted Average) was $170.5 million for Q1 2026 at Acadia Pharmaceuticals, up from $168.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $170.5 million in Q1 2026 to a low of $161654.0 in Q2 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $145.9 million across 5 years, with a median of $164.8 million in 2024.
• Biggest YoY gain for Shares Outstanding (Weighted Average) was 101371.71% in 2023; the steepest drop was 0.64% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $161.7 million in 2022, then gained by 1.32% to $163.8 million in 2023, then climbed by 1.16% to $165.7 million in 2024, then rose by 1.59% to $168.4 million in 2025, then climbed by 1.28% to $170.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $170.5 million (Q1 2026), $168.4 million (Q4 2025), and $167.8 million (Q3 2025), per Business Quant data.